Innaxon产品代理

产品分类 > 科研耗材 > Innaxon产品代理

Innaxon产品代理

Innaxon Therapeutics 是一家位于英国布里斯托尔 Unit DX 的早期开发公司。
Innaxon 的内部生物制药 Toll 样受体 4 (TLR4) 激动剂(Dendrophilin® 和 Novo-Pyrexal®)和获得许可的小分子抑制剂(IAXOTM 化合物)已在治疗癌症的概念验证临床前研究中得到证明 和预防严重的炎症性疾病。 Innaxon 不断寻求与学术、制药和临床研究中心的进一步合作,以利用先天免疫在疫苗佐剂免疫(化学)治疗抗炎剂领域获得治疗益处
价格: 0.00

Innaxon   Therapeutics is an early stage development company based at Unit DX in   Bristol, United Kingdom.

   

Innaxon's in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin® and Novo-Pyrexal®) and in-licensed small molecule inhibitors (IAXOTM compounds) have been shown in proof-of-concept pre-clinical studies to treat cancer and prevent serious inflammatory diseases, respectively. Innaxon continuously seeks further partnerships with academic, pharmaceutical and clinical research centres to harness innate immunity for therapeutic benefit in the field of vaccine adjuvants immuno(chemo)therapy anti-inflammatory agents